$TSHA
Taysha Gene Therapies, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024095082 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $1.788M $1.112M
YoY Change -62.33% -53.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.902M $7.338M
YoY Change -8.01% 22.55%
% of Gross Profit
Research & Development $14.95M $15.07M
YoY Change 26.76% -23.84%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K
YoY Change 0.0% -25.0%
% of Gross Profit
Operating Expenses $27.69M $22.41M
YoY Change 31.86% -13.06%
Operating Profit -$25.90M -$21.30M
YoY Change 59.37% -8.92%
Interest Expense $2.083M $27.00K
YoY Change 41.6% -98.13%
% of Operating Profit
Other Income/Expense, Net $374.0K $371.0K
YoY Change -100.37% -130.56%
Pretax Income -$25.52M -$20.93M
YoY Change -78.2% -14.92%
Income Tax
% Of Pretax Income
Net Earnings -$25.52M -$20.93M
YoY Change -78.2% -14.92%
Net Earnings / Revenue -1427.52% -1882.01%
Basic Earnings Per Share -$0.10 -$0.09
Diluted Earnings Per Share -$0.10 -$0.09
COMMON SHARES
Basic Shares Outstanding 204.9M 187.0M
Diluted Shares Outstanding 267.8M 232.8M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.7M $172.7M
YoY Change -4.02% 283.17%
Cash & Equivalents $157.7M $172.7M
Short-Term Investments
Other Short-Term Assets $465.0K $206.0K
YoY Change 15.1% -59.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $161.6M $178.5M
YoY Change -5.97% 229.8%
LONG-TERM ASSETS
Property, Plant & Equipment $7.613M $10.51M
YoY Change -31.84% -25.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $220.0K $288.0K
YoY Change -27.63% -5.26%
Total Long-Term Assets $18.66M $21.92M
YoY Change -22.12% -20.07%
TOTAL ASSETS
Total Short-Term Assets $161.6M $178.5M
Total Long-Term Assets $18.66M $21.92M
Total Assets $180.2M $200.4M
YoY Change -7.94% 145.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.932M $8.718M
YoY Change -34.41% -19.02%
Accrued Expenses $11.35M $10.73M
YoY Change -9.91% -42.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $381.0K $371.0K
YoY Change 27.0% 10.09%
Total Short-Term Liabilities $29.34M $34.18M
YoY Change -83.74% -32.51%
LONG-TERM LIABILITIES
Long-Term Debt $42.97M $37.84M
YoY Change 11.47% -1.35%
Other Long-Term Liabilities $1.363M $1.380M
YoY Change -64.43% -64.81%
Total Long-Term Liabilities $44.33M $39.22M
YoY Change 4.61% -7.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.34M $34.18M
Total Long-Term Liabilities $44.33M $39.22M
Total Liabilities $91.42M $91.53M
YoY Change -62.67% -22.87%
SHAREHOLDERS EQUITY
Retained Earnings -$583.5M -$558.0M
YoY Change 4.07% 25.76%
Common Stock $2.000K $2.000K
YoY Change 0.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.80M $108.9M
YoY Change
Total Liabilities & Shareholders Equity $180.2M $200.4M
YoY Change -7.94% 145.75%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$25.52M -$20.93M
YoY Change -78.2% -14.92%
Depreciation, Depletion And Amortization $300.0K $300.0K
YoY Change 0.0% -25.0%
Cash From Operating Activities -$21.62M -$21.50M
YoY Change 20.42% 14.58%
INVESTING ACTIVITIES
Capital Expenditures $35.00K $201.0K
YoY Change -518.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$35.00K -$201.0K
YoY Change -99.0% -518.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.595M 70.47M
YoY Change -95.31% 18591.78%
NET CHANGE
Cash From Operating Activities -21.62M -21.50M
Cash From Investing Activities -35.00K -201.0K
Cash From Financing Activities 6.595M 70.47M
Net Change In Cash -15.06M 48.76M
YoY Change -112.63% -365.85%
FREE CASH FLOW
Cash From Operating Activities -$21.62M -$21.50M
Capital Expenditures $35.00K $201.0K
Free Cash Flow -$21.65M -$21.71M
YoY Change 20.61% 15.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001806310
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2024Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2024Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2024Q2 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#Liabilities
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39536
dei Entity Registrant Name
EntityRegistrantName
Taysha Gene Therapies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3199512
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 Pegasus Park Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Ste 1430
dei Entity Address City Or Town
EntityAddressCityOrTown
Dallas
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
75247
dei City Area Code
CityAreaCode
214
dei Local Phone Number
LocalPhoneNumber
612-0000
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
TSHA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
204943306
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172743000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143940000
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
449000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
449000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3278000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3479000
CY2024Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2000000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2000000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
178470000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
149868000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2151000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2151000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10513000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10826000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8971000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9582000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
288000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
304000
CY2024Q2 us-gaap Assets
Assets
200393000
CY2023Q4 us-gaap Assets
Assets
172731000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8718000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6366000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11875000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12284000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13583000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18106000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
34176000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36756000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
37835000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40508000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18134000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18953000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1380000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1577000
CY2024Q2 us-gaap Liabilities
Liabilities
91525000
CY2023Q4 us-gaap Liabilities
Liabilities
97794000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
201381450
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
201381450
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
186960193
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
186960193
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
664457000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
587942000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2405000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-557996000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-513007000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
108868000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
74937000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
200393000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
172731000
CY2024Q2 us-gaap Revenues
Revenues
1112000
CY2023Q2 us-gaap Revenues
Revenues
2395000
us-gaap Revenues
Revenues
4523000
us-gaap Revenues
Revenues
7101000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15073000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19791000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35730000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32305000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7338000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5988000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14422000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14739000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
22411000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
25779000
us-gaap Operating Expenses
OperatingExpenses
50152000
us-gaap Operating Expenses
OperatingExpenses
47044000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21299000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23384000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45629000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39943000
CY2024Q2 tsha Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-195000
tsha Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
142000
CY2024Q2 tsha Change In Fair Value Of Term Loan
ChangeInFairValueOfTermLoan
1279000
tsha Change In Fair Value Of Term Loan
ChangeInFairValueOfTermLoan
2332000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1440000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
223000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3133000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
542000
CY2024Q2 us-gaap Interest Expense
InterestExpense
27000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1440000
us-gaap Interest Expense
InterestExpense
56000
us-gaap Interest Expense
InterestExpense
2814000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
42000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
37000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
371000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1214000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
640000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2277000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-20928000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24598000
us-gaap Net Income Loss
NetIncomeLoss
-44989000
us-gaap Net Income Loss
NetIncomeLoss
-42220000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232821553
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232821553
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64244531
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64244531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232035448
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232035448
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63755435
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63755435
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-20928000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24598000
us-gaap Net Income Loss
NetIncomeLoss
-44989000
us-gaap Net Income Loss
NetIncomeLoss
-42220000
CY2024Q2 tsha Gain Loss On Fair Value Of Terms Loan Attributable To Instrument Specific Credit Risk
GainLossOnFairValueOfTermsLoanAttributableToInstrumentSpecificCreditRisk
2656000
tsha Gain Loss On Fair Value Of Terms Loan Attributable To Instrument Specific Credit Risk
GainLossOnFairValueOfTermsLoanAttributableToInstrumentSpecificCreditRisk
2405000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-18272000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24598000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-42584000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-42220000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
53849000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3332000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2024Q2 tsha Stock Issued During Period Value Gain Loss On Instrument Specific Credit Risk
StockIssuedDuringPeriodValueGainLossOnInstrumentSpecificCreditRisk
2656000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-20928000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
108868000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-14948000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2222000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-24598000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
74937000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6530000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
26000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
tsha Stock Issued During Period Value Gain Loss On Instrument Specific Credit Risk
StockIssuedDuringPeriodValueGainLossOnInstrumentSpecificCreditRisk
2405000
us-gaap Net Income Loss
NetIncomeLoss
-44989000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
108868000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
949000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3897000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
us-gaap Net Income Loss
NetIncomeLoss
-42220000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-37114000
us-gaap Profit Loss
ProfitLoss
-44989000
us-gaap Profit Loss
ProfitLoss
-42220000
us-gaap Depreciation
Depreciation
647000
us-gaap Depreciation
Depreciation
674000
us-gaap Share Based Compensation
ShareBasedCompensation
6530000
us-gaap Share Based Compensation
ShareBasedCompensation
3897000
tsha Research And Development License Expense
ResearchAndDevelopmentLicenseExpense
3500000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
142000
tsha Non Cash Change In Fair Value Of Term Loan
NonCashChangeInFairValueOfTermLoan
-268000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
619000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
603000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-387000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-129000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-509000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2365000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2123000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-1955000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-1324000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4523000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7101000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41302000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38952000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
341000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3852000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-341000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3852000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
18000
tsha Proceeds From Issuance Of Common Stock And Pre Funded Warrants From Underwritten Public Offering Net Of Underwriting Discounts And Sales Commissions And Other Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromUnderwrittenPublicOfferingNetOfUnderwritingDiscountsAndSalesCommissionsAndOtherOfferingCosts
70481000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
387000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
26000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
50000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-43000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-156000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70446000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28803000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-42797000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
146540000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
90517000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175343000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47720000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172743000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45083000
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
2600000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
2637000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175343000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47720000
us-gaap Interest Paid Net
InterestPaidNet
2655000
us-gaap Interest Paid Net
InterestPaidNet
2399000
tsha Issuance Of Warrants In Connection With Private Placement
IssuanceOfWarrantsInConnectionWithPrivatePlacement
252000
tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
3500000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
445000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2020-02-13
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-558000000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
172700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates and assumptions in the Company’s financial statements relate to the determination of the fair value of the common stock prior to the initial public offering (“IPO”) (as an input into stock-based compensation), estimating manufacturing accruals and accrued or prepaid research and development expenses, the measurement of impairment of long-lived assets, the valuation of the Trinity Term Loans that are carried at fair value and the allocation of consideration received in connection with the Astellas Transactions (as defined below). These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
172103000
CY2024Q2 tsha Trinity Term Loans
TrinityTermLoans
37835000
CY2024Q2 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
800000
CY2024Q2 tsha Ssi Warrants
SsiWarrants
596000
CY2024Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
39231000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
142425000
CY2023Q4 tsha Trinity Term Loans
TrinityTermLoans
40508000
CY2023Q4 tsha Success Fee Derivative Liability
SuccessFeeDerivativeLiability
800000
CY2023Q4 tsha Ssi Warrants
SsiWarrants
454000
CY2023Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
41762000
CY2024Q2 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1502000
CY2023Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
1412000
CY2024Q2 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
674000
CY2023Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
802000
CY2024Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
601000
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
681000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
165000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
292000
CY2024Q2 tsha Prepaid Bonus
PrepaidBonus
130000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
206000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
292000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3278000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3479000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14142000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13805000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3629000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2979000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10513000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10826000
CY2024Q2 us-gaap Depreciation
Depreciation
300000
CY2023Q2 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
700000
CY2024Q2 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2613000
CY2023Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3467000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2885000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3423000
CY2024Q2 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
2178000
CY2023Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1851000
CY2024Q2 tsha Lease Liability Current
LeaseLiabilityCurrent
1754000
CY2023Q4 tsha Lease Liability Current
LeaseLiabilityCurrent
1646000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1072000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2024Q2 tsha Warrant Liability Current
WarrantLiabilityCurrent
596000
CY2023Q4 tsha Warrant Liability Current
WarrantLiabilityCurrent
454000
CY2023Q4 tsha Accrued Severance
AccruedSeverance
390000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
777000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
723000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11875000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12284000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
675000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
708000
us-gaap Operating Lease Cost
OperatingLeaseCost
1321000
us-gaap Operating Lease Cost
OperatingLeaseCost
1360000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
198000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
243000
us-gaap Variable Lease Cost
VariableLeaseCost
396000
us-gaap Variable Lease Cost
VariableLeaseCost
486000
CY2024Q2 us-gaap Lease Cost
LeaseCost
873000
CY2023Q2 us-gaap Lease Cost
LeaseCost
951000
us-gaap Lease Cost
LeaseCost
1717000
us-gaap Lease Cost
LeaseCost
1846000
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M17D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M17D
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y4M9D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y9M
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1053
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.1052
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0782
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.078
us-gaap Operating Lease Payments
OperatingLeasePayments
1391000
us-gaap Operating Lease Payments
OperatingLeasePayments
1631000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1423000
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
227000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2910000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
454000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2485000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
399000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2577000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2673000
CY2024Q2 tsha Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
17045000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29113000
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1080000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9596000
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
129000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19517000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
951000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1383000
CY2024Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
371000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18134000
CY2024Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
580000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19517000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
951000
CY2022Q4 tsha Probability Of An Option Exercise
ProbabilityOfAnOptionExercise
0.50
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1100000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
13600000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18100000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
18709000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
21291000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2024Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1300000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2600000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.07
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000
CY2023Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1400000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2700000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7162725
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Plan Adjustments And Amendments In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPlanAdjustmentsAndAmendmentsInPeriod
9348009
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
13717962
tsha Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
609646
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3402418
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3332000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2222000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6530000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3897000
CY2024Q2 tsha Common Stock And Warrants Fair Value Disclosure
CommonStockAndWarrantsFairValueDisclosure
149953
CY2023Q4 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
454000
tsha Change In Fair Value Of Warrants
ChangeInFairValueOfWarrants
142000
CY2024Q2 tsha Warrant Liability Fair Value Disclosure
WarrantLiabilityFairValueDisclosure
596000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20928000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24598000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44989000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42220000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232821553
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232821553
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64244531
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64244531
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
232035448
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
232035448
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63755435
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63755435
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21099690
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9269449
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2024Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000

Files In Submission

Name View Source Status
0000950170-24-095082-index-headers.html Edgar Link pending
0000950170-24-095082-index.html Edgar Link pending
0000950170-24-095082.txt Edgar Link pending
0000950170-24-095082-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img39572056_0.jpg Edgar Link pending
img39572056_1.jpg Edgar Link pending
img39572056_10.jpg Edgar Link pending
img39572056_11.jpg Edgar Link pending
img39572056_12.jpg Edgar Link pending
img39572056_13.jpg Edgar Link pending
img39572056_2.jpg Edgar Link pending
img39572056_3.jpg Edgar Link pending
img39572056_4.jpg Edgar Link pending
img39572056_5.jpg Edgar Link pending
img39572056_6.jpg Edgar Link pending
img39572056_7.jpg Edgar Link pending
img39572056_8.jpg Edgar Link pending
img39572056_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-20240630.htm Edgar Link pending
tsha-20240630.xsd Edgar Link pending
tsha-ex31_1.htm Edgar Link pending
tsha-ex31_2.htm Edgar Link pending
tsha-ex32_1.htm Edgar Link pending
tsha-ex32_2.htm Edgar Link pending
tsha-ex4_1.htm Edgar Link pending
tsha-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable